Switch theme

🎉 M&A multiples are live!
Check it out!

Arovella Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Arovella Therapeutics and similar public comparables like Pharming, Galapagos, and Benevolent AI.

All Drug Development & Therapeutics Multiples Start Free Trial
Arovella Therapeutics logo Arovella Therapeutics logo

Sign up to access all valuation multiples

Arovella Therapeutics Overview

About Arovella Therapeutics

Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.

Founded

1999

HQ

Australia
Employees

14

Website

arovella.com

Financials

Last FY Revenue $11K

Last FY EBITDA -$5.7M

EV

$69.7M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 12K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Arovella Therapeutics Financials

In the most recent fiscal year, Arovella Therapeutics achieved revenue of $11K and an EBITDA of -$5.7M.

Arovella Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Arovella Therapeutics valuation multiples based on analyst estimates

Arovella Therapeutics P&L

NTM Last FY FY 2025 FY 2026 FY 2027
Revenue XXX $11K XXX XXX XXX
Gross Profit XXX $11K XXX XXX XXX
Gross Margin XXX 100% XXX XXX XXX
EBITDA XXX -$5.7M XXX XXX XXX
EBITDA Margin XXX -51144% XXX XXX XXX
EBIT XXX -$7.1M XXX XXX XXX
EBIT Margin XXX -63596% XXX XXX XXX
Net Profit XXX -$5.7M XXX XXX XXX
Net Margin XXX -51447% XXX XXX XXX
Net Debt XXX n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Arovella Therapeutics Stock Performance

As of July 1, 2025, Arovella Therapeutics's stock price is AUD 0 (or $0).

Arovella Therapeutics has current market cap of AUD 119M (or $77.4M), and EV of AUD 107M (or $69.7M).

See Arovella Therapeutics trading valuation data

Arovella Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$69.7M $77.4M XXX XXX XXX XXX n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Arovella Therapeutics Valuation Multiples

As of July 1, 2025, Arovella Therapeutics has market cap of $77.4M and EV of $69.7M.

Arovella Therapeutics's trades at 505.0x EV/Revenue multiple, and -11.9x EV/EBITDA.

Equity research analysts estimate Arovella Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

Arovella Therapeutics's P/E ratio is not available.

See valuation multiples for Arovella Therapeutics and 12K+ public comps

Arovella Therapeutics Financial Valuation Multiples

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Market cap (current) $77.4M XXX $77.4M XXX XXX XXX
EV (current) $69.7M XXX $69.7M XXX XXX XXX
EV/Revenue n/a XXX 505.0x XXX XXX XXX
EV/EBITDA n/a XXX -11.9x XXX XXX XXX
EV/EBIT n/a XXX -10.4x XXX XXX XXX
EV/Gross Profit n/a XXX n/a XXX XXX XXX
P/E n/a XXX -12.5x XXX XXX XXX
EV/FCF n/a XXX -15.9x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Arovella Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Arovella Therapeutics Margins & Growth Rates

Arovella Therapeutics's revenue per employee in the last FY averaged $1K, while opex per employee averaged $0.5M for the same period.

Arovella Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Arovella Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Arovella Therapeutics and other 12K+ public comps

Arovella Therapeutics Operational Valuation Multiples

LTM NTM Last FY FY 2025 FY 2026 FY 2027
Revenue Growth n/a XXX n/a XXX XXX XXX
EBITDA Margin n/a XXX n/a XXX XXX XXX
EBITDA Growth n/a XXX n/a XXX XXX XXX
Rule of 40 n/a XXX n/a XXX XXX XXX
Bessemer Rule of X XXX XXX n/a XXX XXX XXX
Revenue per Employee XXX XXX $1K XXX XXX XXX
Opex per Employee XXX XXX $0.5M XXX XXX XXX
S&M Expenses to Revenue XXX XXX n/a XXX XXX XXX
G&A Expenses to Revenue XXX XXX n/a XXX XXX XXX
R&D Expenses to Revenue XXX XXX 39620% XXX XXX XXX
Opex to Revenue XXX XXX 63696% XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms
Explore Valuation Multiples by Industry
Start Free Trial

Arovella Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Regenerative Medicine comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Arovella Therapeutics M&A and Investment Activity

Arovella Therapeutics acquired  XXX companies to date.

Last acquisition by Arovella Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Arovella Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Arovella Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Start Free Trial

About Arovella Therapeutics

When was Arovella Therapeutics founded? Arovella Therapeutics was founded in 1999.
Where is Arovella Therapeutics headquartered? Arovella Therapeutics is headquartered in Australia.
How many employees does Arovella Therapeutics have? As of today, Arovella Therapeutics has 14 employees.
Is Arovella Therapeutics publicy listed? Yes, Arovella Therapeutics is a public company listed on ASX.
What is the stock symbol of Arovella Therapeutics? Arovella Therapeutics trades under ALA ticker.
When did Arovella Therapeutics go public? Arovella Therapeutics went public in 2002.
Who are competitors of Arovella Therapeutics? Similar companies to Arovella Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Arovella Therapeutics? Arovella Therapeutics's current market cap is $77.4M
Is Arovella Therapeutics profitable? Yes, Arovella Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.

Start Free Trial 🎦 Book a Call